Press Releases

 
Press Releases
  Date Title View
Dec 19, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to ther...
Dec 2, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/...
Dec 2, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptom...
Nov 21, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol ...
Oct 31, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in November 2016. The details are as follows: CreditSuisse 25th Annual Healthcare ConferenceMon...
Oct 27, 2016
Q3 2016 royalty revenue earned up 118% vs Q3 2015 Net income of $15.0 million, or $0.14 per share, and adjusted earnings per share of $0.17 per share Appointed Patrick G. LePore as a director of Innoviva Management will host a conference call and...
Oct 19, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2016 after market close on Thursday, October 27, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss ...
Sep 7, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ:INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in New York on Tuesday, September 13. The details are as follows: Rodman & Renshaw 18th Annual G...
Sep 6, 2016
Improvements in lung function and health-related quality of life supported by statistically significant reductions in exacerbations LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced the presentation of...
Sep 4, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in Ma...
FirstPrevious
3
...
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$12.73 0.25 (2.00%) 06/22/17 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.